业界动态监管公开信息 · WHO

在重重挑战中,各国增加国内投资以保护抗击结核病的进展

WHO News · 2026-11-12 08:00

正文 · 中文译文

根据今日发布的《世界卫生组织(WHO)2026年全球结核病报告》,全球终结结核病(TB)的努力持续取得进展,发病和死亡人数均有所减少。 这一进展的背景是,2024年至2025年间,结核病国内资金增加了14%,达到56亿美元,部分抵消了国际融资同等规模的下降。这一增长凸显了在全球卫生资金紧缩的背景下,国内投资对于维持结核病服务和保护来之不易的健康成果的重要性。 2025年,估计有1060万人罹患结核病,110万人死于结核病。自2015年以来死亡人数下降了35%,自2000年以来治疗估计挽救了8600万人的生命,世界已达到WHO终结结核病战略的第一个死亡率里程碑,尽管比计划晚了五年。而且进展过于缓慢。自2015年以来,全球结核病发病率(每10万人口新发病例数)下降了14%,远未达到2025年下降50%的里程碑目标,结核病仍是单一传染性病原体导致死亡的首要原因。 世界卫生组织总干事谭德塞博士表示:“结核病病例和死亡人数的持续下降非常令人鼓舞,尤其是考虑到许多国家因资金削减而面临的挑战。许多政府已进一步动用自身预算,以保护它们所取得的成果。然而,每年仍有超过100万人死于一种可预防、可治疗的疾病。我们敦促各国和合作伙伴紧急扩大结核病服务的可及性,保护关键资金,并加快开发终结这一流行病的新工具。” 全球结核病负担仍高度集中在30个国家,这些国家占2025年新发结核病患者的88%。各区域进展不均衡。2015年至2025年间,世界卫生组织欧洲区域结核病发病率下降了42%,非洲区域下降了30%,而东南亚区域为18%,东地中海区域仅为6.6%。西太平洋区域没有净变化(0%)。在美洲,2025年发病率连续第五年上升,达到比2015年水平高13%。这些显著差异反映了结核病风险因素、卫生系统实力、服务可及性和持续投资水平方面的差异。 在及时诊断和治疗的可及性方面仍存在重大差距。在2025年估计的1060万新发结核病患者中,840万被诊断,估计有220万要么未被诊断,要么未被报告。仅59%的新诊断患者使用了世界卫生组织推荐的快速诊断检测,远低于2027年100%的目标。 耐药结核病仍是一项重大公共卫生挑战。在2025年估计的37万耐利福平结核病患者中,仅42%接受了治疗。在接受治疗者中,世界卫生组织(WHO)推荐的六个月治疗方案的使用率大幅上升,从2024年的18%增至2025年的42%。 结核病研究投入严重不足。2023年研究经费为12亿美元,不足2027年所需50亿美元年度目标四分之一。迫切需要加大投资,以研发和推广新疫苗、新诊断工具和新疗法。 WHO呼吁各国政府和合作伙伴加强政治承诺,保护和增加对结核病的可持续筹资,迅速扩大预防、快速诊断和有效治疗的可及性,并加快对新工具的投资。必须大幅加快进展,使世界重回终结结核病流行的轨道。 关于WHO 世界卫生组织致力于增进全人类福祉并以科学为指导,领导和倡导全球努力,让世界各地每个人都享有平等机会获得安全健康的生活。我们是联合国在150多个地点连接国家、伙伴和民众的卫生机构——引领全球应对突发卫生事件、预防疾病、解决健康问题的根本原因并扩大药物和卫生保健的可及性。我们的使命是支持所有国家促进、提供和保护健康。“携手为健康,与科学同行”是2026年世界卫生日的主题,标志着为期一年的宣传活动,旨在突出科学作为保护全球健康与福祉的基础。

正文 · 英文原文

Global efforts to end tuberculosis (TB) continue to make progress, with fewer people falling ill and dying from the disease, according to the World Health Organization (WHO) Global Tuberculosis Report 2026 released today. This progress comes as domestic funding for TB increased by 14% to US$ 5.6 billion between 2024 and 2025, in part offsetting a decline in international financing of a similar scale. This increase underscores the importance of domestic investment in sustaining TB services and protecting hard-won health gains amid a global health funding crunch. In 2025, an estimated 10.6 million people developed TB and 1.1 million people died from TB. With deaths falling by 35% since 2015 and treatment saving an estimated 86 million lives since 2000, the world has reached the first mortality milestone of WHO’s End TB Strategy although five years later than planned. And progress has come too slowly. Since 2015, the global TB incidence rate (new cases per 100 000 population) has declined by 14%, far short of the 50% reduction milestone for 2025, and TB remains the leading cause of death from a single infectious agent. "The continued decline in TB cases and deaths is very encouraging, especially given the challenges many countries have faced from funding cuts," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Many governments have dug deeper into their own budgets to protect the gains they have made. And yet, more than one million people still die each year from a disease that is preventable and treatable. We urge countries and partners to urgently expand access to TB services, protect essential funding and accelerate the development of new tools to end this epidemic.” The global TB burden remains heavily concentrated in 30 countries, which account for 88% of people who developed TB in 2025. Progress was uneven across regions. Between 2015 and 2025, TB incidence fell by 42% in the WHO European Region and 30% in the African Region, compared with 18% in South-East Asia and just 6.6% in the Eastern Mediterranean. There was no net change (0%) in the Western Pacific. In the Americas, incidence rose for the fifth consecutive year in 2025, reaching 13% above 2015 levels. These stark differences reflect variations in the TB risk factors, the strength of health systems, access to services and levels of sustained investment. Major gaps in access to timely diagnosis and treatment remain. Of the estimated 10.6 million people who developed TB in 2025, 8.4 million were diagnosed, leaving an estimated 2.2 million either undiagnosed or unreported. Just 59% of newly diagnosed patients were tested using a WHO-recommended rapid diagnostic test, far short of the 100% target for 2027. Drug-resistant TB remains a major public health challenge. Of the estimated 370 000 people who developed rifampicin-resistant TB in 2025, only 42% received treatment. Among those treated, uptake of the WHO-recommended six-month treatment regimen increased substantially, from 18% in 2024 to 42% in 2025. Investment in TB research is critically insufficient. Research funding stood at US$ 1.2 billion in 2023, less than one quarter of the required US$ 5 billion annual target for 2027. Greater investment is urgently needed to develop and roll out new vaccines, diagnostics and treatments. WHO is calling on governments and partners to strengthen political commitment, protect and increase sustainable financing for TB, rapidly expand access to prevention, rapid diagnosis and effective treatment, and accelerate investment in new tools. Progress must be much faster to put the world back on track towards ending the TB epidemic. About WHO Dedicated to the well-being of all people and guided by science, WHO leads and champions global efforts to give everyone, everywhere, an equal chance at a safe and healthy life. We are the United Nations’ agency for health that connects nations, partners and people in more than 150 locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to support all countries to promote, provide and protect health. “Together for health. Stand with science”, the theme of World Health Day 2026, marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide.

English
Amid challenges, countries increase domestic investment to protect progress against tuberculosis
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界